The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT)…
BALTIMORE–(BUSINESS WIRE)–AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing vital new therapies based on a novel peptide platform, today…
Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases…
Arthroscopy is one of the most common procedures performed in the United States (almost 5,000 per day), yet its underlying…
Metal-organic frameworks are compounds that are set to solve some tough challenges: producing water in the desert, removing greenhouse gases…
Drugs which target the BCMA receptor look set to feature prominently at this year’s American Society of Haematology (ASH) meeting,…
Nine abstracts accepted, including two oral presentations HOUSTON, Nov. 01, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in…